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Evaluating the Role of a Galanin Enhancer
Genotype on a Range of Metabolic,
Depressive and Addictive Phenotypes.
Am J Med Genet Part B 165B:654–664.There is a largebodyof pre-clinical and someclinical data to link the
neuropeptide galanin to a range of physiological and pathological
functions that include metabolism, depression, and addiction. An
enhancer region upstream of the human GAL transcriptional start
site has previously been characterised. In-vitro transfection studies
in rat hypothalamic neurons demonstrated that the CA allele was
40% less active than theGGallele in driving galanin expression.Our
hypothesis was to investigate the effect of this galanin enhancer
genotypeonarangeofvariables that relate to theknownfunctionsof
the galaninergic system in the Avon Longitudinal Study of Parents
and Children (ALSPAC) cohort of young adults (N¼ 169–6,078).
Initial findings showed a positive relationship of cannabis usage
(OR¼ 2.070,P¼ 0.007,N¼ 406(individualswhohadusedcannabis
at least once within the last 12 months, total sample size 2731) with
the GG haplotype, consistent with the previous published data
linkinggalaninwithanincreasedreleaseofdopamine.Asoursample
size was relatively small we replicated the analysis in a larger cohort
of 2,224 African Americans and 1,840 European Americans, but no
discernible trend across genotypeswas observed for the relationship
with cannabisusage. Further,we foundnoassociationof thegalanin
enhancer genotypewith any of the other pathophysiological param-
etersmeasured. These findings emphasise that preclinical data does
not always predict clinical outcomes in cohort studies, noting that
association studies are subject to multiple confounders.
 2014 The Authors. American Journal of Medical Genetics Part B: Neuropsychiatric
Genetics published by Wiley Periodicals, Inc.
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The neuropeptide galanin (Tatemoto et al., 1983) has a discreet
pattern of expression in a number of areas in the central and
peripheral nervous system that include the hypothalamus, hip-
pocampus, substantia nigra, ventral tegmental area, nucleus
accumbens (NAc), locus coeruleus, spinal cord, and the dorsal
root ganglia (Melander et al., 1985; Melander et al., 1986a; Mel-
ander et al., 1986b; Hokfelt et al., 1987; Villar et al., 1989;
Wiesenfeld et al., 1992). There is a wealth of pharmacological
and genetic pre-clinical data to link the neuropeptide and its three
G-protein coupled receptors (Gal1, Gal2, and Gal3) to a range of
physiological and pathological functions. These include metab-
olism, feeding and endocrinology, cognition, epilepsy, chronic
anxiety and depression, addiction, neuroprotection, neuronal
regeneration, and pain (see recent reviews (Lang et al., 2007;
Ogren et al., 2010; Picciotto et al., 2010)). Some, but by nomeans
all, of these rodent findings are paralleled by human studies
demonstrating associations between single nucleotide polymor-
phisms (SNPs) in the GAL gene and/or one of its three receptors,
and depression or anxiety disorders (Unschuld et al., 2008; Wray
et al., 2010; Juhasz et al., 2014) and addictive behaviours that
include smoking (Gold et al., 2012), alcohol (Belfer et al., 2006),
and heroin (Levran et al., 2008). To date, there are no studies that
link the galaninergic system to dietary fat intake or weight
regulation in humans, though a single study has shown a rela-
tionship with elevated triglyceride levels in familial combined
hyperlipidaemia (Plaisier et al., 2009).
Davidson et al. previously used comparative genomics to identify
and then characterise a highly conserved region 42kb upstream of the
humanGAL transcriptional start site that was termedGAL5.1 (David-
sonet al., 2011).TheGAL5.1 enhancer (i.e., a regionofDNAwhich can
beboundwithproteins toactivate transcriptionofa gene) contains two
polymorphisms; rs2513280 (C/G) and rs2513281 (A/G), that occur in
two allelic combinations (GG or CA) where the dominant GG allele
occurred in 70–83% of the human population. In-vitro transfection
studies in rat hypothalamic neurons demonstrated that the CA allele
was 40% less active than the GG allele in driving galanin expression
(Davidson et al., 2011). Both SNPs were found to be in linkage
disequilibrium (LD) with another SNP (rs2156464) previously associ-
atedwithmajor depressive disorder.More recently, the GGhaplotype,
which predicts greater galanin expression, has been shown to be
associated with problem drinking in women (Nikolova et al., 2013).
Here we have used the Avon Longitudinal Study of Parents and
Children (ALSPAC) cohort to study whether the galanin enhancer
haplotype is linked to a range of variables that relate to the known
pre-clinical functions of the galaninergic system. These include
body mass index, blood pressure, cognition, anxiety, and depres-
sion scores and usage of alcohol, cannabis, and smoking.Our initial
findings demonstrated a relationship of cannabis usagewith theGG
haplotype, which predicts greater galanin expression (Davidson
et al., 2011). These findings however were not replicated in either
the Young Netherlands Twin Register (YNTR) or the Yale-UPenn
study, a large cohort of African (AAs) and European Americans
(EAs). Further, and despite the significant rodent pre-clinical data
sets, we found no association of the galanin enhancer haplotype
with the other pathophysiological parameters measured.MATERIALS AND METHODS
Cohort Descriptions
The ALSPAC study uses a population-based cohort to investigate
genetic and environmental factors that affect the health and
development of children. The study methods have been described
in detail elsewhere (Boyd et al., 2013) (http://www.bristol.ac.uk/
alspac). Briefly, 14,541 pregnant women residents in the former
region of Avon, UK, with an expected delivery date between 1st
April 1991 and 31st December 1992, were eligible to take part in
ALSPAC. There were 14,062 live born children, 13,988 of whom
were alive at 1 year. Ethical approval was obtained from the
ALSPACLawandEthicsCommittee and the Southmead, Frenchay,
UBHTandWestonResearchEthicsCommittees.Written informed
consent was obtained from parents for all measurements made.
YNTR is a population based study including more than 70,000
Dutch twins and their siblings, born after 1985 (van Beijsterveldt
et al., 2013). Briefly, the YNTR participants are registered at birth
and phenotyped longitudinally in surveys focused on behaviour
problems, health, and lifestyle. Up to the age of 14, the surveys are
completed by parents and teachers. From age 14 onward, the data
are collected by self-report, basedonprior parentalwritten consent.
The study protocol was approved by theMedical ethical committee
of the VU Medical Centre, Amsterdam, The Netherlands
(IRB00002991). For the present replication study, a sample of
362 individuals (mean age¼ 17.96; range¼ 14–27.5 years; 51.4%
males) was available. For these subjects both genotype data were
available as well as data on cannabis frequency. If more than one
time point was available, data collected in the most recent survey
were included in this analysis.
The Yale-UPenn study included 1,840 EA and 2,244 AA subjects
who had both genotype data and measures of cannabis use. All
subjects were recruited for studies of the genetics of drug (opioid or
cocaine) or alcohol dependence (Gelernter et al., 2013). The sample
consisted of small nuclear families (SNFs) originally collected for
linkage studies (primarily full sibs, half sibs, and parents, generally
nomore than one parent per family) and unrelated individuals who
were recruited in the Eastern US (CT, PA, MA, and SC). Subjects
gave written informed consent as approved by the institutional
review board at each site, and certificates of confidentiality were
obtained from NIDA and NIAAA.Data Collection
We initially identified four broad areas that galanin has been linked
to in previous epidemiological studies; metabolism, cognition,
depression, and addiction (see recent reviews (Lang et al., 2007;
Ogren et al., 2010; Picciotto et al., 2010)). We then selected traits
from the phenotypically-rich ALSPAC cohort which best repre-
sented these epidemiological areas of interest (see below and
supporting information).Metabolism
Height was measured to the nearest 0.1 cm using a Leicester height
measure (HoltainCrosswell,Dyfed,UK)andweightwasmeasured to
thenearest 0.1 kgusingTanita electronic scales.Waist circumference
656 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bwas measured to the nearest 1mm at the mid-point between
the lower ribs and the pelvic bone with a flexible tape. Whole
body dual-emission X-ray absorptiometry (DXA) determined fat
and bone mass was assessed at the clinic using a Lunar Prodigy
scanner (GELunar,Madison,WI)withpaediatric scanningsoftware.
Blood Pressure was measured with a Dinamap 9301 vital moni-
tor completed by trained staff using the appropriate cuff size. Two
readings of both systolic and diastolic blood pressure were taken
when the study participants were at rest and the mean of each were
used as a measurement in our analysis. Fasting blood samples were
taken fromparticipants who attended the age14 clinic (median age:
15 years and 5 months, IQR: 15 years and 3 months–15 years and 7
months) after they had been asked to fast for at least six hours and
then immediately spun and frozen at 80˚C. Measurements were
then assayed three to nine months after the samples were taken.
Plasma lipid concentrations (including total cholesterol and tri-
glycerides) were measured by modification of the standard lipid
research clinics protocol with enzymatic reagents for lipid deter-
mination (Myers et al., 2000).Cognition
Measurements for participants reading level were taken at the age
7-clinic (median age: 7 years and 5 months, IQR: 7 years and
5 months–7 years and 6 months) using the Wechsler Objective
ReadingDimensions (WORD) test (Rust et al., 1993). The following
cognitive function measures were recorded at the age 8 clinic
(median age: 8 years and 7 months, IQR: 8 years and 6 months–
8 years and 8 months). IQ was measured using the Weschler
Intelligence Scale for Children (Weschler et al., 1992) (3rd UK
edition (WISC–III). A shortened version of the scale was applied by
trained psychologists who used alternate items for all subtests (with
the exceptionof the coding subtest) in the scale. Short-termmemory
was also measured at the age 8 clinic using an adaption of the
Nonword Repetition Test (Gathercole et al., 1994). Participants
were asked to repeat 12 nonsense words comprised of three, four or
five syllables after hearing them on an audio cassette. The outcome
variable was recorded as the number of words repeated correctly.
Speech and language were tested using items from the oral expres-
sion and language comprehension subsets of theWechslerObjective
Language Dimensions (Rust, 1996) (WOLD). At the age 10 clinic
(median age: 10 years and 7months, IQR: 10 years and 5months–10
and years and 9 months) working memory was assessed using the
Counting Span working memory task (Case et al., 1982) which
involved counting and recalling numbers of dots on a screen. Two
scores were recorded as separate variables, the span score which
represents the number of correctly recalled sets of dots (maximum
score of 5 in increments of 0.5) and a global score based on the
number of screens correctly answered (maximum score of 42).Depression
Four thousand sevenhundred thirty eight individualswhoattended
the age 17 clinic (median age: 17 years and 9months, IQR: 17 years
and 7months–17 years and 11months) completed a computerised
self-reported questionnaire for the revised version of the Clinical
Interview Schedule (CIS-R). CIS-R has been designed to identifythe nature and severity of any neurotic symptoms or presence of
neurosis experienced over the previous seven days (Lewis
et al., 1992). A variable was then generated using the five depression
symptom scores to get a continuous depression score. We dicho-
tomised this variable to obtain a binary trait, where scores greater
than 12 were classed as a clinically significant levels of distress.
Furthermore, the ICD-10 diagnosis was also derived from the CIS-
R data which allowed us to generate a categorical variable for
analysis (Organization, 1993).
Participants were also invited to a PLIKS (psychosis like symp-
toms) semi-structured interview (Horwoodet al., 2008) (PLIKSi) at
the age 11 clinic (median age: 11 years and 9months, IQR: 11 years
and 7months–11 years and 10months). The interview consisted of
12 core questions concerning the occurrence of hallucinations,
delusions, and experiences of thought interference over the past six
months. For more detail, seven of the questions were derived with
slight modification from DISC-IV (Shaffer et al., 2000) and the
other five from section 17 of the Schedules for Clinical Assessment
in Neuropsychiatry (SCAN) version 2.0 (Organization, 1994). The
interviewer categorised each PLIKs as either “not present”, “sus-
pected” or “definitely present”, which were coded as 0, 1 or 2
respectively and combined to make an overall score.Addiction
At both the age 14 clinic (median age: 15 years and 5 months, IQR:
15 years and 3months–15 years and 7months) and the age 17 clinic
(median age: 17 years and9months, IQR: 17 years and7months–17
years and 11months) data on self-reported alcohol intake, cannabis
use and frequency of tobacco smoking in the past month was
collected. A subset of participants (N¼ 2,933) at the age 17 clinic
had two cotinine level measurements (ng/ml) taken which were
assessed using immunoassay from blood plasma and the mean was
used as a measurement in our analysis. As we were interested in
quantifying addiction we removed all non-smokers from subse-
quent analyses (N¼ 1,428). A dichotomised phenotype was also
calculated for this data using a cut-off of 50 ng/ml in order to
distinguish daily smokers from non-daily smokers, based on data
from a Finnish sample that used similar methods for cotinine assay
(Vartiainen et al., 2002).
Also at the age 17 clinic, participants were asked to complete a
six item cannabis abuse screen test (CAST) (Legleye et al., 2012)
which entailed questions about cannabis use in the past year. This
outcome was dichotomised for our analysis to distinguish be-
tween heavy cannabis users (i.e., a CAST score of one or more)
and infrequent cannabis users. The problem gambling severity
index (PGSI, derived from the longer Canadian Problem Gam-
bling Inventory (Miller et al., 2013)) was administered to par-
ticipants who had reportedly engaged in any of 16 types of
gambling in the past year. A PGSI score of 1 or more was used
to indicate a participant who had shown signs of problem
gambling in that time.
Yale-UPenn: Subjects were administered the Semi-Structured
Assessment for Drug Dependence and Alcoholism (SSADDA)
(Pierucci-Lagha et al., 2005) to determine the frequency of cannabis
use and time spent drinking heavily (detailed phenotype descrip-
tion below) as well as other major psychiatric traits. Subjects with
RICHARDSON ET AL. 657bipolar affective disorder or schizophrenia were excluded, except as
relatives. All subjects signed written informed consent as approved
by IRBs at each clinical site; and certificates of confidentiality were
obtained from NIAAA and NIDA.ALSPAC Genotyping
Davidson et al., [2011] previously analysed the GAL5.1 haplotype
region (rs2513280 (C/G) and rs2513281 (A/G)). However, these
two SNPs are in perfect LD inEuropean populations (R2¼ 1.00 and
D’¼ 1.00 in CEU according toHapMap) whichmakes rs2513280 a
perfect proxy for the GAL5.1 haplotype. All genotyping was per-
formed by KBiosciences (Herts, UK) using their own system of
fluorescence based competitive allele-specific PCR (KASPar).
Details of assay design are available from the KBiosciences website
(http://www.kbioscience.co.uk). 8,365 offspring were successfully
genotyped for the rs2513280 (GAL) variant. Studyparticipantswith
a reported non-white ethnic background (N¼ 21) were excluded
from analyses. A further 48 offspring were removed as they were
either the second born child or born in a multiple pregnancy. This
left a sample size of 8,296 which was in the Hardy-Weinberg
Equilibrium (x2¼ 0.26, P¼ 0.610).Statistical Analysis
ALSPAC: Pearson’s x2-test was used to examine if the genotype
distributions were consistent with Hardy–Weinberg equilibrium
(HWE).Genotypeswere coded as 0, 1 or 2 based on thenumber ofG
alleles, as Davidson et al., [2011] reported the GG haplotype to be
associatedwithhigher activity of galanin. Linear regressionwasused
to investigate per-allele associations of rs2513280 with continuous
phenotypes.Multinomial logistic regressionwas applied to calculate
odds ratios (OR) for categorical traits using the addictive model of
inheritance. Phenotypes thatwere not normally distributedwere log
transformedon the log10 scale to approximate univariatenormality
before conducting any analyses. Multiple testing was corrected for
using the Bonferroni correction (Bonferroni, 1936). Any possible
interaction between genotype and sex was assessed using the likeli-
hood ratio test to compare two regression models, one which was
simply adjusted for sex and another which also included an inter-
action term for genotypesex. If this analysis provided evidence of
an interaction we analysed males and females separately to verifyTABLE I. Association of rs2513280 (GAL) Geno
Mean age (years) N C/C C/G
7.6 6,075 16.178 (1.922) 16.199 (2
9.9 5,819 17.722 (2.755) 17.655 (2
10.7 5,622 18.153 (2.852) 18.212 (3
11.8 5,421 18.777 (3.100) 19.109 (3
13.9 4,746 19.880 (3.137) 20.388 (3
15.5 4,176 21.182 (3.490) 21.363 (3
Genotype data are presented as mean (standard deviation).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/Cwhether any association appeared when stratifying by sex. This was
of particular interest for any relationship identified between
rs2513280 and alcohol as there has been a previously reported
gender-specific association with problem drinking at this locus
(Nikolova et al., 2013). Stata 12.0 software (StataCorp, College
Station, TX) was used for all statistical analyses.
YNTR: The analysis was performed in Plink (Purcell et al., 2007)
byusing a logistic regressionmodel.As the sample included sibships
of sizes 1–4, consisting of monozygotic and dizygotic twins and
additional siblings, a sandwich correction (Williams, 2000) was
used to take data clustering into account. Sex and age at the last
survey and three principal components were included as covariates.
Yale-UPenn: Two phenotypes were tested in the US cohort. The
firstwas abinary variable indicatingwhether, at the timeof subject’s
lives duringwhich theywere using cannabismost heavily, they used
the drug 13 or more times per month. Association was tested with
rs2513280using logistic regressionmodels adjusted for age, sex, and
three principal components of ancestry. The SNP was tested
separately in EAs and AAs. Generalized estimating equations
were used to correct the standard error for the fact that the sample
contained related individuals.RESULTS
Metabolism
Body mass index and waist circumference were analysed as contin-
uous traits at six different time points (Tables I and II), and there
was no evidence that rs2513280 was associated with either of these
phenotypes. Systolic and diastolic blood pressure were analysed as
continuous traits across four time points but there was also little
evidence of an association or discernible trend across genotypes
(Table III). Dual-energy X-ray absorptiometry (DXA)-assessed fat
and bone mass was analysed at four time points and although the
results for fatmasswere negative therewas an addictive trend across
genotypes at ages 9 and 13 for bone mass (P¼ 0.014 and 0.023
respectively, Table IV). However, these results were not strong
enough to survive the correction for multiple comparisons at a 5%
level. Fasting triglycerides were analysed as a continuous traits but
the result were not associated with rs2513280 (P¼ 0.207). We then
used the 90th percentile to classify cases and controls for hyper-
triglyceridemia (the same cut-off as used by Plaisier et al., 2009).types with BMI (kg/m2) in the ALSPAC Cohort
G/G Padd Pdom Prec
.082) 16.239 (2.023) 0.416 0.811 0.403
.893) 17.687 (2.810) 0.729 0.817 0.640
.104) 18.201 (3.060) 0.977 0.942 0.955
.462) 19.026 (3.337) 0.861 0.412 0.643
.477) 20.327 (3.442) 0.801 0.162 0.856
.530) 21.413 (3.500) 0.468 0.515 0.548
¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
TABLE II. Association of rs2513280 (GAL) Genotypes With Waist Circumference (cm) in the ALSPAC Cohort
Mean age (years) N C/C C/G G/G Padd Pdom Prec
7.6 6,078 56.357 (4.731) 56.293 (5.219) 56.467 (5.161) 0.266 0.948 0.219
9.9 5,867 62.830 (7.638) 62.787 (7.855) 62.894 (7.671) 0.600 0.958 0.566
10.7 5,659 65.269 (7.890) 65.476 (8.612) 65.523 (8.662) 0.799 0.823 0.832
11.8 5,423 67.487 (8.181) 68.401 (9.471) 68.204 (9.373) 0.836 0.429 0.625
13.9 4,741 70.872 (8.528) 72.114 (8.861) 72.050 (9.310) 0.707 0.170 0.973
15.5 3,454 75.574 (9.183) 76.533 (8.907) 76.645 (8.823) 0.383 0.275 0.531
Genotype data are presented as mean (standard deviation).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/C¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
TABLE III. Association of rs2513280 (GAL) Genotypes With Blood Pressure (mmHg) in the ALSPAC Cohort
Mean age (years) N Type C/C C/G G/G Padd Pdom Prec
7.6 6,013 Systolic 98.578 (8.550) 98.644 (9.058) 98.932 (9.259) 0.275 0.731 0.265
Diastolic 55.799 (5.592) 56.409 (6.590) 56.301 (6.665) 0.986 0.358 0.749
9.9 5,806 Systolic 102.821 (8.875) 102.710 (9.280) 102.710 (9.280) 0.897 0.897 0.918
Diastolic 57.959 (6.336) 57.431 (6.357) 57.359 (6.388) 0.393 0.298 0.537
11.8 5,378 Systolic 104.706 (10.054) 105.494 (9.858) 105.496 (9.810) 0.660 0.386 0.832
Diastolic 58.399 (6.155) 58.899 (6.509) 58.659 (6.585) 0.452 0.594 0.309
15.5 4,087 Systolic 122.208 (10.398) 122.660 (10.928) 123.098 (10.890) 0.187 0.493 0.207
Diastolic 67.609 (8.107) 67.512 (8.946) 67.412 (8.696) 0.709 0.850 0.720
Genotype data are presented as mean (standard deviation).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/C¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
658 AMERICAN JOURNAL OF MEDICAL GENETICS PART BThere was an increased odds per allele towards the G allele,
suggesting that higher galanin expression contributes to increased
risk of hypertriglyceridemia, although the sample was too small to
identify evidence of an association (OR: 1.15 (95% CI 0.90–1.47)
P¼ 0.267, N¼ 2863).TABLE IV. Association of rs2513280 (GAL) Genotypes With D
Fat/bone Mean age (years) N C/C
Fat 9.9 5,608 8.374 (4.729)
Bone 1.209 (0.188)
Fat 11.8 5,355 11.075 (6.008) 1
Bone 1.543 (0.277)
Fat 13.9 4,688 12.699 (7.497) 1
Bone 2.036 (0.367)
Fat 15.5 4,012 14.402 (8.663) 1
Bone 2.462 (0.436)
Genotype data are presented as mean (standard deviation).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/CCognition
We analysed data collected from theWORD, IQ, Nonword repeti-
tion,WOLDand theCountingSpanWorkingMemoryTask tests as
continuous variables (WORD median age: 7 years and 5 months;XA-assessed Fat and Bone Mass (kg) in the ALSPAC Cohort
C/G G/G Padd Pdom Prec
8.488 (5.086) 8.537 (5.029) 0.610 0.654 0.670
1.209 (0.205) 1.224 (0.199) 0.014 0.528 0.010
1.794 (6.857) 11.617 (6.662) 0.815 0.385 0.588
1.546 (0.302) 1.558 (0.291) 0.181 0.661 0.174
3.866 (8.011) 13.738 (8.002) 0.831 0.100 0.761
2.090 (0.412) 2.112 (0.404) 0.023 0.077 0.047
5.099 (9.062) 15.413 (9.135) 0.188 0.271 0.263
2.491 (0.476) 2.515 (0.467) 0.087 0.343 0.105
¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
TABLE V. Association of rs2513280 (GAL) Genotypes With Measures of Cognition in the ALSPAC cohort
Test Mean age (years) N C/C C/G G/G Padd Pdom Prec
WORD 7.5 5,986 28.060 (9.489) 28.409 (8.847) 28.472 (9.393) 0.657 0.627 0.734
IQ 8.7 5,517 104.946 (18.336) 104.109 (15.961) 105.042 (16.508) 0.124 0.914 0.076
Nonword 8.7 5,532 7.422 (2.360) 7.236 (2.499) 7.270 (2.522) 0.813 0.381 0.981
WOLD 8.7 5,561 7.419 (2.079) 7.391 (1.894) 7.550 (1.981) 0.032 0.455 0.030
Count–Span score 10.6 5,271 1.221 (0.220) 1.179 (0.341) 1.194 (0.320) 0.434 0.292 0.216
Count–Global score 10.6 5,271 18.520 (7.624) 18.315 (6.897) 18.355 (7.566) 0.274 0.927 0.205
Genotype data are presented as mean (standard deviation).
WORD,Wechsler ObjectiveReading Dimensions (number of correctwords read (maximumof 55words)); IQ, IQ test; Nonword, NonwordRepetition test (0–12 correct answers, childrenwere asked to repeat
12 “nonwords”);WOLD, Listening comprehension and oral expression (0-15 correct answers); Count, Counting spanworkingmemory task; Span score (maximumscore of 5 in increments of 0.5) andGlobal
score (maximum score of 42).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/C¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
RICHARDSON ET AL. 659Counting Span Working Memory Task median age: 10 years and
7 months; all other measures taken at median age: 8 years and 7
months) (Table V). We found some evidence of association be-
tween rs2513280 and the offspring’s results for the WOLD test
(P¼ 0.032), although it was not robust enough to survive the
correction for multiple comparisons.
Depression
Depression scores (median age: 7 years and 5 months, IQR: 7 years
and 5months–7 years and 6months) based on the CIS-R question-
naire data were analysed as continuous and categorical variables,
although neither suggested that rs2513280 was associated with
depression using this criteria (P¼ 0.338 and P¼ 0.824 respectively,
N¼ 3,420). Furthermore, using the ICD-10 diagnosis criteria to
diagnose cases for depression provided no evidence of an associa-
tion (OR¼ 1.086, P¼ 0.529, N¼ 3,408). Similarly, psychosis like
symptoms (PLIKS) (median age: 11 years and 9 months, IQR:
11 years and 7 months–11 years and 10 months) was also not
associated with rs2513280 (P¼ 0.373).TABLE VI. Association of rs2513280 (GAL) Genotypes
Phenotype Mean age (years) N Ca
CAST score 17.8 406
Frequency of cannabis use 17.8 169
1 Day ‘Binge drinking‘ 15.5 3538
Frequency of alcohol use 15.5 2272
Frequency of alcohol use 17.8 1530
Daily versus non-daily cigarette smokers 17.8 878
PGSI score 17.8 2353
Genotype data are presented as percentage.
CAST, Cannabis abuse screening test—CAST Score of 1 or more¼ 1, CAST Score of 0¼ 0 (having sti
Frequency of cannabis use, 4þ times per week¼ 1, 2–3 times per week¼ 0.
1 day ‘Binge drinking‘– participants were asked whether they spent a great deal of their day drin
Frequency of alcohol use—drinking 2–3 times per week¼ 1, monthly 0.
PGSI, Problem gambling severity index—Problematic gambling exhibited in the past¼ 1, non-proble
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2).Addiction
Results for analyses between rs2513280 and all addiction related
phenotypes are presented in Table VI.
Cannabis. When quantifying addiction using frequency of
cannabis used (median age: 17 years and 9 months, IQR: 17 years
and 7 months–17 years and 11 months) we observed strong
evidence of an association when comparing very frequent users
(4þ times per week) with occasional users (2–3 times per week)
(OR¼ 2.243,P¼ 0.018,N¼ 169).We alsoobserved increasedodds
when comparingheavyusers (i.e. aCAST scoreofoneormore)with
occasional users (a CAST score of 0 despite using cannabis at least
once in the last year) (OR¼ 2.070, P¼ 0.007, N¼ 406). However,
as our sample size for these analyses were relatively small we sought
out replication to strengthen the evidence that the observed signal
was robust. The association of rs2513280 with the frequency of
cannabis usage was analysed in the Yale-UPenn cohort (mean
age¼ 40.0; range¼ 16–79 years) and the YNTR sample (mean
age¼ 17.96; range¼ 14–27.5 years).Obtaining a similar phenotype
definition to the one used in the ALSPAC cohort was challenging asWith Addiction Related Traits in the ALSPAC Cohort
se (%) Control (%) C/C (%) C/G (%) G/G (%) OR Padd
32.3 67.6 2.2 25.6 72.2 2.070 0.007
48.6 51.4 2.3 23.7 74.0 2.243 0.018
8.8 91.2 2.2 26.6 71.2 1.338 0.022
9.1 90.9 2.2 25.0 72.8 1.286 0.124
49.8 50.2 2.2 25.7 72.1 1.226 0.046
20.2 79.8 2.2 26.0 71.8 1.001 0.997
8.4 91.6 2.2 25.6 72.2 1.175 0.299
ll used cannabis within the last 12 months).
king alcohol over the last 2 years (yes¼ 1, no ¼0).
m or no gambling in the past year¼ 0.
660 AMERICAN JOURNAL OF MEDICAL GENETICS PART Bthe observation periods were different. The frequency of cannabis
use was therefore analysed in the Yale-UPenn cohort by comparing
subjects who used cannabis 12 days or less of the month with those
whoused cannabis 13days ormorepermonth. In theYNTRcohort,
light cannabis users (1–4 times in the last month) were compared
withheavy users (more than 20 times permonth). For both, thiswas
as comparable as we could get to our initial phenotype definition in
the ALSPAC cohort. However, no discernible trend across geno-
typeswasobserved in either cohort (Yale-UPenn:AAs—OR¼ 1.10,
P¼ 0.368, N¼ 2244, EAs—OR¼ 1.07, P¼ 0.620, N¼ 1840;
YNTR: OR¼ 0.284, P¼ 0.138, N¼ 74).
Alcohol. At the age 15 clinic (median age: 15 years and
5 months, IQR: 15 years and 3 months–15 years and 7 months),
teenagers were asked whether they spent a great deal of their day
drinking alcohol over the last two years (i.e., at least one day ‘binge
drinking’). Analysing this trait provided evidence to suggest
rs2513280 was associated with this addiction-related phenotype
(OR¼ 1.338, P¼ 0.022, N¼ 3538). Frequency of alcohol intake
was also analysed at two time points by calculating the odds of those
who reportedly drank alcohol 2–3 times per week compared to
those who drank monthly or less. There was little evidence of an
association with rs2513280 at age 14 (OR¼ 1.286, P¼ 0.124,
N¼ 2272). However, at the age 17 clinic (median age: 17 years
and9months, IQR: 17years and7months–17 years and11months)
there was nominal evidence of association (OR¼ 1.226, P¼ 0.046,
N¼ 1530) although it was not robust enough to survive the
correction for multiple comparisons. The relationships between
rs2513280 and phenotypes based on alcohol intake were further
examined to verify whether there was evidence of an interaction
between genotype and gender.However, results from these analyses
did little to support this in both the observed association with
drinking for a great deal of the day (P¼ 0.288) and drinking alcohol
2–3 times per week compared to monthly or less (P¼ 0.314).
Smoking. Our analysis for both measurements of cotinine
levels as continuous traits (median age: 17 years and 9 months,
IQR: 17 years and 7 months–17 years and 11 months) resulted in
little evidence of association with rs2513280 (Table VII). Fur-
thermore, dichotomising this phenotype using a cut-off of 50 ng/
ml in order to calculate odds of daily smokers versus non-daily
suggested rs2513280 did not have a strong effect on addiction
using this trait (OR¼ 1.072, P¼ 0.620). There was no discernible
trend across genotypes for frequency of cigarette smoking on a
daily basis (P¼ 0.359,N¼ 373) and comparing the odds for those
who smoked on a daily basis compared to non-daily smokers
(OR¼ 1.00, P¼ 0.997, N¼ 878) suggest rs2513280 was not con-TABLE VII. Association of rs2513280 (GAL) Genotypes With Cotini
Measurement N C/C C/G
1 1,428 42.428 (74.903) 33.627 (80.5
2 1,428 43.281 (79.543) 34.402 (83.4
Genotype data are presented as mean (standard deviation).
Padd, P-value for addictive effect (C/C¼ 0, C/G¼ 1, G/G¼ 2); Pdom, P-value for dominant effect (C/Ctributing to frequency of cigarette smoking. These results were
concordant with large genome-wide association studies which
found no evidence of association with cigarette smoking with
SNPs in theGAL gene region (Tobacco andGenetics, 2010; David
et al., 2012; Yoon et al., 2012).
Gambling. Comparing individuals who had shown signs of
problematic gambling in the last year (i.e. a PGSI score of 1 ormore)
with those who did not, provided little evidence to suggest that
rs2513280 was associated with gambling addiction (OR¼ 1.175,
P¼ 0.299, N¼ 2353).DISCUSSION
Wehave undertaken extensive analyses to investigate the effects of a
galanin enhancer genotype (rs2513280) on a range of phenotypes
that are related to known functions of the galaninergic system (see
recent reviews (Lang et al., 2007; Ogren et al., 2010; Picciotto
et al., 2010)). Despite finding evidence of association with cannabis
use in the ALSPAC cohort, we were unable to replicate this effect in
the YNTR and Yale-UPenn cohorts. We found little evidence to
suggest that SNP rs2513280 has an impact on any of the other traits
analysed in our evaluations.
Galanin has been shown to increase alcohol consumption under
a number of pre-clinical experimental paradigms. Administration
of the neuropeptide into the paraventricular nucleus (PVN) or
third ventricle potently increases alcohol intake innormal adult rats
and those selected for high intake (Lewis et al., 2004; Rada
et al., 2004; Schneider et al., 2007). Conversely, the non-selective
galanin antagonist M40 decreases alcohol consumption and inhib-
its galanin-stimulated alcohol intake (Lewis et al., 2004; Rada
et al., 2004). These findings may initially appear to be at odds
with other studies showing that galanin decreases the responses to
other drugs of abuse such asmorphine, cocaine, and amphetamines
(reviewed in (Picciotto et al., 2010)). It should be noted however
that alcohol has a significant caloric value andmay therefore utilise
the same hypothalamic circuits that are known to mediate the
stimulatory effects of galanin on food intake (Leibowitz et al., 2003;
Schneider et al., 2007). Galanin injection into the PVN increases
dopamine release in the nucleus accumbens (Rada et al., 1998)
which would be consistent with the rewarding effects of alcohol
(reviewed in (Picciotto et al., 2010)). In support of these rodent
findings a number of studies have shown an association between
alcoholism and SNPs in the genes for galanin or Gal3 receptor, but
not Gal1 and Gal2 (Belfer et al., 2006; Belfer et al., 2007; Nikolova
et al., 2013) and most recently, the GG haplotype has been shownne Levels (ng/ml) Addiction Related Traits in the ALSPAC Cohort
G/G Padd Pdom Prec
44) 38.765 (85.076) 0.457 0.763 0.361
48) 41.540 (89.560) 0.283 0.831 0.210
¼ 0, C/G¼ 1, G/G¼ 1); Prec, P-value for recessive effect (C/C¼ 0, C/G¼ 0, G/G¼ 1).
RICHARDSON ET AL. 661to be associated with problem drinking in women (Nikolova
et al., 2013). Of note, recent genome-wide association studies of
alcohol use failed to identify any genetic variants in the galaninergic
system that reached genome-wide significance (Kapoor et al., 2013;
Gelernter et al., 2014). To date, we have been unable to identify any
pre-clinical or clinical published studies that link galanin to can-
nabis usage.
The GG haplotype of the GAL5.1 enhancer region of the galanin
gene has been evolutionary conserved and represents the major
haplotype in human populations. Davidson et al. showed a 40%
higher level of galanin expression than the CA allele in transfected
cultured rat hypothalamic neurons (Davidson et al., 2011). The
failure to replicate the initial association in the ALSPAC cohort of
rs2513280 with the frequency of cannabis use in the Yale-UPenn
and YNTR cohorts may be due in part to the difficulties we faced in
phenotype harmonisation between the cohorts. Supplementary
Tables SI and SIII compare the ALSPAC cohort with both replica-
tion samples and reflect the challenge we encountered for replica-
tion due to the disparity between samples, particularly for age and
sample size. We attempted to dichotomise cannabis usage in the
YNTR cohort to resemble the phenotype definition in the ALSPAC
cohort as closely as possible; however this caused our replication
sample size to become relatively small. Of significance, whilst
initiation of cannabis use and its withdrawal are both heritable,
little is known about the underlying genetic aetiology. Recentmeta-
analyses and genome-wide association studies of cannabis use
with >10,000 individuals failed to identify any genetic variants
that reached genome-wide significance (Le et al., 2009; Verweij
et al., 2013a; Verweij et al., 2013b).
It is also important to focuson the lackof associationof rs2513280
with the many other phenotypes that might have been expected to
demonstrate a link with galanin, based on the pre-clinical rodent
findings. We did not identify an association of rs2513280 with
smoking, which is consistent with previous studies that have only
shown an association with an intronic SNP in the Gal1 gene (Gold
et al., 2012). Similarly, the absence of a relationship with bodymass
index, waist circumference, fat mass, and blood pressure are all
consistent with other negative association studies previously
reported for the galaninergic system (Schauble et al., 2005; Sutton
et al., 2006). A previous study (Plaisier et al., 2009) demonstrated an
association in Dutch, Finnish, and Mexican familial combined
hyperlipidaemia families with an allele residing 5.6 kb upstream
of the transcriptional start site of the GAL gene. The lack of an
association of rs2513280 with fasting triglyceride levels in the
ALSPAC cohort may be explained by the fact that the vast majority
of the cohorts have normal triglyceride levels and thus are most
unlikely to have a combined hyperlipidaemia. Further, it is possible
that the two galanin enhancer regions which are more than 35 kb
apart may differentially regulate galanin expression in differing
tissues or cell types. We also failed to identify an association of
rs2513280with thevarious tests of cognition, andareunawareof any
previous reports testing linkage of polymorphisms in any of genes
involved in the galaninergic system with measures of cognition.
In contrast to the above, the lack of an association of rs2513280
withdepressionwas initially surprising sinceDavidson et al., [2011]
had shown it to be in LD with another closely located SNP
(rs2156464, R2¼ 0.687) in the galanin promoter which has beenassociated with major depressive disorder in adults (Wray et al.,
2010). The lack of an association with depression in the ALSPAC
cohort may be explained in part by the small sample size and the
mean age of the subjects (17.8 years) when the depression scores
were measured. At that time point only 8.4% of the cohort had an
ICD-10 diagnosis for depression (whether mild, moderate or
severe), and thus it is not surprising that we failed to identify an
association with rs2513280. Further, it is possible that environ-
mentally-induced epigenetic modification of GAL5.1 might be
partly responsible for reducing the significance of some of these
association studies. For example, hypomethylation of enhancer
regions that regulate neuropeptide expression in the hypothalamus
have been shown to be strongly influenced by early life stress
(Murgatroyd et al., 2009).
Other SNPs within theGAL gene region to have been previously
implicated in disease susceptibility include rs2187331 (R2¼ 0.687
with rs2513280), which has been linked with increased triglyceride
levels (16), and rs948854 (R2¼ 0.462 with rs2513280) which has
shown evidence of association with opioid dependence (Beer et al.,
2013). As we did not find evidence to suggest that rs2513280 was
implicated in triglyceride synthesis and as it was not in high linkage
disequilibrium with rs948854. Other previously reported SNPs
within the GAL gene region did not appear to be in linkage
disequilibrium with rs2513280 (rs694066 (R2¼ 0.007) and
rs7101947 (R2¼ 0.135)) (Ruano et al., 2006).
According toHapMap there seems to be some variation between
the minor allele frequencies of rs2513280 across different ethnic
groups. As the ALSPAC cohort consists predominantly of individ-
uals with amaternally reported European ethnic origin wewere not
able to robustly evaluate how this variationmay affect the results of
our study. However, it is important for future studies that investi-
gate the effects of rs2513280 using amore ethnically diverse sample
to adjust for this possible population stratification accordingly.
In summary, we have used a large longitudinal cohort of over
10,000 young adults and failed to demonstrate an association be-
tween a SNP in a galanin enhancer region,which predicts an increase
in galanin expression, with any of the pathophysiological parameters
measured. Our results also illustrate the importance of seeking
independent replication of initial promising findings, even when
these are informed by relevant neurobiology and preclinical data
(Munafo and Gage, 2013). It is increasingly clear that the contribu-
tion of individual common genetic variants to complex behavioural
traits will be very small, so that very large samples will be required to
reliably detect these (Munafo and Flint, 2011). Whilst genome-wide
methods are hampered by the need to harmonise phenotypes across
contributing studies, and the requirement to achieve genome-wide
significance, these have typically generated more reproducible find-
ings than candidate gene methods (Flint and Munafo, 2013).ACKNOWLEDGMENTS
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